NEW YORK (GenomeWeb News) — Critical Therapeutics today said Beckman Coulter has exercised a licensing option to continue using its high mobility group box 1 technology.
CT said the companies penned a licensing deal in 2005 that gave BC the use of HMGB1 to develop an immunoassay to detect inflammatory diseases. HMGB1 has been identified as a possible mediator of tissue damage caused by inflammation.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.